That zinc lozenge might help you stave off a cold, but it won’t do much to help you against serious bacterial infections like those caused by the sexually transmitted bacteria Neisseria gonorrhoeae. In fact, investigators at Georgia State University’s Institute for Biomedical Sciences have just found that that blocking zinc uptake in N. gonorrhoeae can prevent further infection from this pathogen. Findings from the new study were published recently in PLOS Pathogens through an article titled “The Novel Interaction Between Neisseria gonorrhoeae TdfJ and Human S100A7 Allows Gonococci to Subvert Host Zinc Restriction.”

The researchers are optimistic that their new findings could be used to move gonorrhea vaccine development forward because they provide insight into how to block the growth of this pathogen. No vaccine has been developed to prevent this serious infection.

There are more than 820,000 new cases of gonorrhea each year in the United States, and more than half of these cases are estimated to be among young people 15- to 24-years-old, according to the Centers for Disease Control and Prevention. Neisseria gonorrhoeae, the pathogen that causes gonorrhea, is considered to be an urgent threat because it has developed resistance to nearly every drug used for treatment, making it difficult to cure.

Untreated gonorrhea can cause severe and permanent health problems in women and men, and most women don’t have symptoms. In women, untreated gonorrhea can cause pelvic inflammatory disease, which leads to infertility and ectopic pregnancies, life-threatening pregnancies that occur when a fertilized egg implants outside the womb.

“Our results are significant because N. gonorrhoeae will die if it can’t get enough zinc,” explained senior study investigator Cynthia Cornelissen, PhD, professor, and director of the Center for Translational Immunology in the Institute for Biomedical Sciences at Georgia State. “The study suggests a way to halt the growth of this sexually transmitted infection in the host’s body.”

N. gonorrhoeae is challenging to prevent and treat because it has an arsenal of conserved outer membrane proteins that allow the pathogen to overcome nutritional immunity, the host’s strategy for sequestering essential nutrients away from invading bacteria and handicapping their infectious ability.

The bacterial pathogen produces eight known outer membrane transporters. Four are used for the acquisition of iron or iron chelates. Two of the remaining transporters, TdfH and TdfJ, facilitate zinc uptake. In previous work, Cornelissen’s group has shown that TdfH binds to Calprotectin (a member of the S100 protein family) and extracts its zinc, which is then internalized by N. gonorrhoeae.

This study sought to evaluate whether other proteins in the S100 family have the ability to support gonococcal growth by zinc acquisition. Cornelissen’s group found that TdfJ binds directly to S100A7, from which it internalizes zinc. This interaction is only detected with the human version of S100A7, which is significant because gonorrhea infection only occurs in humans, and thus the ability to use only human S100A7 contributes to the species specificity of the pathogen.

“A group of gonococcal outer membrane proteins called TonB-dependent transporters (TdTs) have been implicated as promising vaccine targets, as they are well-conserved and expressed across gonococcal isolates and play a vital role in allowing the pathogen to acquire essential nutrients during infection of the human host, the authors wrote. “Here, we describe the conservation and regulation of TdfJ, a gonococcal TdT whose homologs are ubiquitous in the genus Neisseria. We show that TdfJ binds directly to S100A7, a host protein that normally sequesters zinc away from invading pathogens. This novel interaction enables N. gonorrhoeae to strip S100A7 of chelated zinc for its own use. Furthermore, we show that another zinc-binding human protein, S100A12, is also utilized by N. gonorrhoeae as a zinc source by an as-yet-unidentified mechanism.”

Interestingly, the researchers found that N. gonorrhoeae overpowers human nutritional immunity through the interaction between TdfJ and human S100A7, allowing the pathogen to overcome the host’s zinc restriction and continue to grow. The research team plans on using their findings from this study and previous studies on zinc uptake in N. gonorrhoeae to develop a vaccine to protect against the pathogen. Using an approach called “starve and kill,” they will attempt to starve N. gonorrhoeae of the necessary nutrients (zinc and iron) to prevent it from growing and potentially even infecting the host.

“This study provides insight into the functional role of the TdTs during infection and highlights these proteins as promising targets for both vaccine and antimicrobial therapy development,” the authors concluded.

Previous articleMelanoma Checkpoint Therapy More Potent in Combination with Nanovaccine
Next articleDeaths from Heart Disease and Stroke Have Almost Stopped Declining in High-Income Countries